Research
Hormonal
Gastrointestinally-mediated glucose disposal (GIGD), a measure of integrated glucose handling including glucagon suppression, is significantly reduced in Type 2 Diabetes and correlates with obesity.
Managing Type 2 Diabetes involves more than just stimulating insulin; it requires suppressing glucagon. Weight loss helps restore this balance, improving how your body disposes of glucose after a meal.
GoodSupportsHIGH confidence
GIGD was significantly lower in participants with T2D than in those with NGT, and significantly negatively correlated with the area under the curve (AUC)-glucose, BMI, and AUC-glucagon.
Why this rating
Clear statistical difference (p=0.012) between T2D and NGT groups for GIGD.
Source
The integrated incretin effect is reduced by both glucose intolerance and obesity in Japanese subjects
Akihiro Hamasaki et al. · Frontiers in Endocrinology · 2024
DOI 10.3389/fendo.2024.1301352
cross_sectional · n=28Cited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →